Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.
Regional Medical Center
1155 Mill St

Children's Hospital
1155 Mill St

Rehabilitation Hospital
1495 Mill St

South Meadows Medical Center
10101 Double R Blvd

Skilled Nursing
1835 Oddie Blvd

Carson Valley Medical Center
1107 HWY 395
Center for Advanced Medicine B
1500 E 2nd St

Center for Advanced Medicine C
75 Pringle Way

Institute for Heart & Vascular Health
1155 Mill St

Institute for Cancer
1155 Mill St
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.
Regional Medical Center
1155 Mill St

Children's Hospital
1155 Mill St

Rehabilitation Hospital
1495 Mill St

South Meadows Medical Center
10101 Double R Blvd

Skilled Nursing
1835 Oddie Blvd

Carson Valley Medical Center
1107 HWY 395
Center for Advanced Medicine B
1500 E 2nd St

Center for Advanced Medicine C
75 Pringle Way

Institute for Heart & Vascular Health
1155 Mill St

Institute for Cancer
1155 Mill St
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Regional Medical Center

1155 Mill St Reno, NV 89502
775-982-4100


Renown Regional Medical Center
1155 Mill St, Reno, NV 89502
Renown Health serves a 17-county region with a total population in excess of 750,000. Our facilities include two medical centers, a rehabilitation hospital, a skilled nursing facility, numerous medical group and urgent care facilities, and the region's most trusted health insurance provider, Hometown Health. 775-982-5000

Renown Children's Hospital

1155 Mill St Reno, NV 89502
775-982-KIDS (5437)

Renown Children's Hospital
1155 Mill St, Reno, NV 89502
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Rehabilitation Hospital

1495 Mill St Reno, NV 89502
775-982-3500


Renown Rebabilitation Hospital - 1495 Mill St
1495 Mill St, Reno, NV 89502
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown South Meadows
Medical Center

10101 Double R Blvd Reno, NV 89521
775-982-7000


Renown South Meadows - 10101 Double R Blvd
10101 Double R Blvd, Reno, NV 89521
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Carson Valley Medical Center

1107 Hwy 395 Gardnerville, NV 89410
775-782-1550


Carson Valley Medical Center - 1107 Highway 395
1107 Highway 395, Gardnerville, NV 89410
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Skilled Nursing

1835 Oddie Blvd Sparks, NV 89431
775-982-3232


Renown Skilled Nursing - 1835 Oddie Blvd
1835 Oddie Boulevard, Sparks, NV 89431
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Health Urgent Care

775-982-5000

Renown Health Urgent Care
9 convenient locations
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.
Renown Lab Services offers convenient access to complete your lab work with 10 locations close to your home or work. For your convenience, many of the locations are located inside or next to Renown hospitals and medical groups. Extended and Saturday hours are available at some locations.
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Center for Advanced Medicine B at Renown Regional

1500 E 2nd St Reno, NV 89502
775-982-4100


Center for Advanced Medicine B - 1500 E. 2nd St
1500 E. 2nd St., Reno, NV 89502
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Center for Advanced Medicine C at Renown Regional

75 Pringle Way Reno, NV 89502
775-982-4100


Center for Advanced Medicine C - 75 Pringle Way
75 Pringle Way, Reno, NV 89502
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Institute Heart & Vascular Health

1155 Mill St Reno, NV 89502
775-982-7888


Institute for Heart & Vascular Health - 1155 Mill St
1155 Mill St, Reno, NV 89502
Based in Reno, Nevada, Renown Health continues to be the regional healthcare leader, serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is Reno’s only locally owned, not-for-profit health network offering more services than all other local healthcare networks combined.

Renown Institute for Cancer

1155 Mill St Reno, NV 89502
775-982-5638


Renown Institute for Cancer - 1155 Mill St
1155 Mill St, Reno, NV 89502
 Back Close X

HealthDay Daily News
Print This Page     Email this to a Friend

New Drug May Extend Survival for Some Prostate Cancer Patients

Study found Xofigo also improved quality of life for those whose cancer had spread to the bones

By Amy Norton
HealthDay Reporter

WEDNESDAY, July 17 (HealthDay News) -- A newly approved drug that emits radioactive particles can help extend the lives of certain men with advanced prostate cancer, a clinical trial finds.

Experts said the results, published in the July 18 issue of the New England Journal of Medicine, offer some good news for men whose cancer has migrated to the bones -- a common and painful feature of advanced prostate cancer.

The drug, which is marketed as Xofigo, is intended for men with cancer that has spread to the bones despite standard treatment to cut the body's levels of testosterone -- the "male" hormone that fuels prostate cancer growth.

Known generically as radium-223, the drug emits radioactive particles that zero in on cancerous tissue in the bones. In the new study, researchers found that men given Xofigo had a lower death rate and better quality of life than those on standard treatment only.

Xofigo is already on the market in the United States, after getting an expedited approval from the U.S. Food and Drug Administration in May. That was based on findings from the current trial, which was designed and funded by drug makers Bayer and Algeta.

The study was supposed to last three years, but it was stopped early when interim results showed that men on the drug had a clear survival advantage.

Those patients typically survived for 15 months, versus 11 months among men who received an inactive placebo in addition to standard treatment.

That "might not sound like very much," said lead researcher Dr. Christopher Parker, of Royal Marsden Hospital in the United Kingdom. "On the other hand, this represents a 30 percent improvement in survival in a group of patients who had a very poor prognosis."

More important, the extra time tended to be better-quality time, said a cancer specialist who was not involved in the research.

If a cancer therapy gives people more months of life, but those months are filled with debilitating treatment side effects, then the longer survival may not be worth it, said Dr. Neha Vapiwala, a radiation oncologist at the University of Pennsylvania in Philadelphia.

"In this study, their quality of life was improved, in addition to their longer survival," she noted.

The study included 921 men with prostate cancer that had spread to the bones but not other organs. All had received standard hormonal therapy and, in some cases, the chemotherapy drug docetaxel. (Some men were not healthy enough to receive the chemo, and others did not want it.)

About 600 men were randomly assigned to have injections of Xofigo, once a month for six months; the rest were given placebo injections and standard care, including more hormonal therapy or external radiation to try to treat the bone pain.

At the time the trial was stopped, 35 percent of the Xofigo group had died, versus 46 percent of the placebo group. One-quarter of men on the drug reported a "meaningful" improvement in their quality of life, compared with 16 percent of the placebo group.

There were side effects. Anywhere from 18 percent to 36 percent of men suffered nausea, diarrhea, constipation or fatigue; but most of those symptoms were just as common in the placebo group.

There were, though, more serious problems related to the body's ability to produce blood cells, which is handled by the bone marrow. Twelve percent of men on Xofigo developed thrombocytopenia, a drop in blood cells called platelets that can cause serious bleeding. That compared with 6 percent of the placebo group.

Another 5 percent of men on the drug developed neutropenia, a drop in the body's infection-fighting white blood cells.

For most men with prostate cancer, the tumor is slow-growing and never progresses to the point where it threatens their lives. According to the American Cancer Society, nearly all men with cancer confined to the prostate gland or nearby lymph nodes are still alive five years after their diagnosis -- and many can opt to delay having any treatment, and have the cancer monitored instead.

But the outlook is much more dim for men whose prostate cancer spreads to the bones or other distant sites. Only 28 percent are alive five years after their diagnosis.

"There are men who have serious disease, and in the years they do live they are often in pain, and in and out of the hospital," Vapiwala said.

Xofigo gives an option for at least some of them, she said.

Because the drug emits radioactive particles, it has to be given by a radiation oncologist or nuclear medicine specialist. So, smaller community hospitals may not be able to offer it, Vapiwala noted.

There's also cost. The course of six injections rings up at nearly $70,000.

The ultimate role of the drug in treating advanced prostate cancer is still in question, according to Vapiwala. A few other treatments -- hormonal therapy and two chemo drugs -- have been approved for these same patients in the past couple of years. And it's not known if Xofigo could, for example, be combined with any of those treatments.

"The right combination of treatments, and the right sequence, is still being studied," Vapiwala said.

And Parker added that no one knows yet if the drug could help people with other types of cancer that has spread to the bone. "In theory," he said, that should be the case. "But we do not yet have any data on this."

He noted that an ongoing trial is studying radium-223 for breast cancer that has spread to the bones.

More information

The American Cancer Society has more on prostate cancer treatment.


SOURCES: Christopher Parker, M.D., Royal Marsden Hospital, Sutton, U.K.; Neha Vapiwala, M.D., assistant professor, radiation oncology, University of Pennsylvania School of Medicine, Philadelphia; July 18, 2013, New England Journal of Medicine

Health News Copyright © 2013 HealthDay. All rights reserved.